Status:
AVAILABLE
An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
Lead Sponsor:
Eisai Inc.
Conditions:
Lennox Gastaut Syndrome
Eligibility:
All Genders
4+ years
Brief Summary
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until...
Eligibility Criteria
Inclusion
- Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.
Exclusion
- Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03778424
Last Update
July 17 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Generała Tadeusza Kościuszki 52
Kielce, Poland
2
Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
Poznan, Poland